Related Experiment Video
Updated: Jul 16, 2025
Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells
Published on: August 7, 2021
Development of Potent and Selective Coactivator-Associated Arginine Methyltransferase 1 (CARM1) Degraders
Haibo Xie1, Megan S Bacabac2, Min Ma1
1Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Abstract:
CARM1 is amplified or overexpressed in many cancer types, and its overexpression correlates with poor prognosis. Potent small-molecule inhibitors for CARM1 have been developed, but the cellular efficacy of the CARM1 inhibitors is limited. We herein report the development of the proteolysis targeting chimera (PROTAC) for CARM1, which contains a CARM1 ligand TP-064, a linker, and a VHL E3 ligase ligand. Compound 3b elicited potent cellular degradation activity (DC50 = 8 nM and Dmax > 95%) in a few hours. Compound 3b degraded CARM1 in VHL- and proteasome-dependent manner and was highly selective for CARM1 over other protein arginine methyltransferases. CARM1 degradation by 3b resulted in potent downregulation of CARM1 substrate methylation and inhibition of cancer cell migration in cell-based assays. Thus, CARM1 PROTACs can be used to interrogate CARM1's cellular functions and potentially be developed as therapeutic agents for targeting CARM1-driven cancers.
Insights
Researchers developed a novel proteolysis targeting chimera (PROTAC) for CARM1, a protein linked to cancer. This CARM1 PROTAC effectively degrades the target protein in cells, offering potential therapeutic applications for CARM1-driven cancers.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- CARM1 (protein arginine methyltransferase) is overexpressed in many cancers, correlating with poor prognosis.
- Existing small-molecule CARM1 inhibitors show limited cellular efficacy.
- Targeting CARM1 is a promising strategy for cancer therapy.
Purpose of the Study:
- To develop a proteolysis targeting chimera (PROTAC) for CARM1.
- To evaluate the cellular efficacy and selectivity of the developed CARM1 PROTAC.
- To investigate the functional consequences of CARM1 degradation in cancer cells.
Main Methods:
- Design and synthesis of a CARM1 PROTAC (compound 3b) comprising a CARM1 ligand (TP-064), a linker, and a VHL E3 ligase ligand.
- Assessment of cellular degradation activity (DC50, Dmax) and selectivity over other protein arginine methyltransferases.
- Evaluation of CARM1 substrate methylation and cancer cell migration inhibition in cell-based assays.
Main Results:
- Compound 3b demonstrated potent CARM1 degradation (DC50 = 8 nM, Dmax > 95%) within hours.
- CARM1 degradation by compound 3b was VHL- and proteasome-dependent and highly selective.
- CARM1 degradation led to downregulation of substrate methylation and inhibited cancer cell migration.
Conclusions:
- CARM1 PROTACs are effective tools for achieving potent and selective CARM1 degradation in cells.
- CARM1 PROTACs can be utilized to study CARM1's cellular functions.
- CARM1 PROTACs hold potential as therapeutic agents for CARM1-driven cancers.
Related Concept Videos
02:04Co-activators and Co-repressors
02:04Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
01:32Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
02:58Regulated Protein Degradation
02:25Spreading of Chromatin Modifications
Writers
The writer...